Life Sciences Tools and Services
Company Overview of VIB BV
VIB BV is a life sciences research institute that performs basic research into the molecular foundations of life. It focuses on translating scientific results into pharmaceutical, agricultural, and industrial applications. The company performs research in the areas of bioinformatics, cancer, cardiovascular medicine, developmental biology, inflammation and immunity, microbiology, neuroscience, plant biology, proteomics, structural biology, and systems biology. Its research services include sequencing and genotyping; sequencing, microarrays, and transcriptomics; assay development and compound screening; protein production, purification, and analysis; proteomics analysis; nanobody production an...
Founded in 1995
32 9 244 66 11
32 9 244 66 10
Key Executives for VIB BV
Compensation as of Fiscal Year 2015.
VIB BV Key Developments
ThromboGenics and VIB Launch New Oncology Company, Oncurious NV
Apr 14 15
ThromboGenics NV announced the foundation of Oncurious NV, a new oncology company that will develop TB-403 for the treatment of pediatric brain tumors. VIB will become a shareholder alongside ThromboGenics in this new oncology venture. ThromboGenics will be the majority shareholder. VIB will become a shareholder alongside ThromboGenics in this new oncology venture. ThromboGenics will be the majority shareholder. TB-403 is a humanized monoclonal antibody against placental growth factor. PlGF is expressed in several types of cancer, including medulloblastoma. High expression of the PlGF receptor neuropilin 1 has been shown to correlate with poor overall survival. Medulloblastoma is a rare, life-threatening brain tumor that mainly affects children. Treatment with TB-403 in relevant animal models for medulloblastoma has demonstrated beneficial effects on tumor growth and survival. The antibody can potentially be used in other pediatric cancer indications, including neuroblastoma. Oncurious now plans to start a Phase I/IIa program with TB-403 in medulloblastoma patients. Enrollment of the first patient is expected for the end of 2015. The favorable safety profile of TB-403 has already been demonstrated in clinical trials in patients with other diseases. BioInvent International AB will act as a co-development partner for this oncology project. ThromboGenics has retained the exclusive license for use of TB-403 in ophthalmic indications.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries